


“Maintaining the rhythm”

Zurich, March 17, 2016



Diagnostic services for  
physicians and their patients.  
Always. Everywhere.



# Media - Investor Conference

## Savoy Hotel, Zurich

Stephan Rietiker, M.D.  
CEO

Andrew Moore  
designated CFO

This communication contains statements that constitute “forward-looking statements”. Such forward-looking statements include, without limitation, statements relating to the Company’s financial condition, results of operations and business and certain of the Company’s strategic plans and objectives. Because these forward-looking statements are subject to risks and uncertainties, actual and / or future results may differ materially from those expressed in or implied by the statements. Many of these risks and uncertainties relate to factors which are beyond the Company’s ability to control or estimate precisely. Examples of such factors include future market conditions, currency fluctuations, the behavior of other market participants, the actions of governmental regulators and other risk factors detailed in Company’s past and future filings and reports as well as in past and future filings, press releases, reports and other information posted on the Group companies’ websites. Readers are cautioned not to put undue reliance on forward-looking statements, which reflect only our opinions as of the date of this presentation. LifeWatch AG disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.

- This presentation does not constitute an offer to sell or a solicitation to purchase any securities of LifeWatch AG. Any such decision must not be made on the basis of the information provided in this presentation.
- This presentation must not be distributed in or into the United States of America.

## 2015 Financial Highlights



- 2015 revenues up 8.3% to USD 106.63 million
- 9.8% growth in cardiac monitoring business in the USA
- EBITDA for the year of USD 14.4 million; EBITDA margin of 13.5%
- Adjusted EBITDA of USD 15.6 million; adjusted EBITDA margin of 14.6%
- EBIT of USD 6.3 million; EBIT margin of 5.9%
- Adjusted EBIT of USD 7.5 million; adjusted EBIT margin of 7.0%
- Net Income of USD 1.6 million

## 2015 Accomplishments













- International expansion underway – JV signed for cardiac monitoring in Turkey
- Partnerships signed – Kyocera and AliveCor
- Acquisition of Flexlife Health Inc., signalling a first move into relevant co-morbidities
- FDA submissions made for the MCT 1-Lead patch, our ACT software on an Android operating system and the Vital Signs Monitoring System
- FDA clearance delayed as a result of more stringent FDA processes but received in 2015 for the ACT software on an Android operating system and in early 2016 for the MCT 1-Lead patch and the Vital signs monitoring system
- Two significant legal case victories
- Signed 81 new or amended agreements for ACT, INR and HST services giving a total of over 600 managed care contracts with provider networks

- Delay in FDA clearance of the MCT 1-lead patch and lower device sales led to lower than expected sales
- Delay in the FDA clearance of the ACT software on an Android operating system led to significant additional costs
- Re-assessment of technical and market entry requirements has led to a significant delay in the launch of the Vital signs monitoring system
- Delay in Vital signs monitoring system causes write-off of remaining LifeWatch V inventory
- Internal IT systems recognized as limiting factor for future growth and international expansion

# Evolution of Cardiac Monitoring Devices



										
	Digital holter	King of Hearts Express	MicroER	Explorer	LifeStar AF Express	MCT ACT III	ACT Ex	ACT Elite	ECG-Mini	VSP
Launch year	-	1994	1996	1999	2001	2008	2009	2012	2016	2016
Discontinuation year	-	2016	2016	-	-	-	-	-	-	-
Format	Monitor	Monitor	Monitor	Monitor	Monitor	Monitor + gateway	Monitor + gateway	Monitor + gateway	Patch + brain + gateway	Patch + brain + gateway
Auto-detect	Tachycardia Bradycardia AF	x	x	x	✓	✓	✓	✓	✓	-
	Pause	x	x	x	x	✓	✓	✓	✓	-
Max recording time	48h	5m	6 x 30s	5m	10m	1 month			-	
Data transmission	Manual upload	Via landline				Via GSM				
Data type	ECG					ECG, respiration rate, temperature, saturation, positioning				
Auto-detect/auto-send	x	x	x	x	x	✓	✓	✓	✓	-

Low Frequent ← Diagnostic Yield Symptoms → High Infrequent

Replaced in 2016 by AliveCor mobile ECG


Launch Q2 / 2016

**FUTURE**

# 2015 Business Statistics (1)




### Average Selling Price (USD)





## Patient Numbers by Product Type




# Digital Health: a paradigm shift in healthcare



- Uberification of Healthcare
- Only constant is change
- Change creates opportunities
- Move from traditional fee-for-service to pay-for-performance models (and how much they pay)
- Focus on patient centric vision for our business

LifeWatch is evaluating the opportunities and is well positioned to become a significant player in this space



- 2015 revenues up 8.3% to USD 106.63 million thanks to strong organic growth in core business; US market growth was 9.8%
- 2015 gross margin dropped to 52.1% mainly as a result of additional depreciation and IT costs as well as a one-off item of USD 1.2 million
- EBIT for the year of USD 6.3 million, equivalent to an EBIT margin of 5.9%; adjusted EBIT amounted to USD 7.5 million, equivalent to an EBIT margin of 7.0%;
- EBITDA for the year of USD 14.4 million, equivalent to an EBITDA margin of 13.5%; adjusted EBITDA of nearly USD 15.6 million achieved giving a margin of 14.6%;
- Net Income of only USD 1.6 million as a result of Turkey JV start-up costs and higher tax charge

# Profit & Loss Statement



USD millions	First Half 2015	Second Half 2015	Total 2015	2014	+/- in %
<b>Total revenues</b>	52.513	54.114	106.627	98.471	8.3%
Total cost of revenues	(24.764)	(26.273)	(51.037)	(45.287)	
<b>Gross profit</b>	<b>27.749</b>	<b>27.841</b>	<b>55.590</b>	<b>53.184</b>	<b>4.5%</b>
<i>GP margin</i>	52.8%	51.4%	52.1%	54.0%	
Research & development expenses	(1.983)	(2.157)	(4.140)	(5.562)	-25.6%
<i>in % sales</i>	3.8%	4.0%	3.9%	5.6%	
Selling & marketing expenses	(9.453)	(9.343)	(18.796)	(22.682)	-17.1%
<i>in % sales</i>	18.0%	17.3%	17.6%	23.0%	
General & administrative expenses	(12.502)	(13.814)	(26.316)	(25.139)	4.7%
<i>in % sales</i>	26.4%	24.7%	25.5%	25.5%	
Legal expenses and other expenses, net	0	0	0	0.499	
<b>EBIT</b>	<b>3.811</b>	<b>2.527</b>	<b>6.338</b>	<b>0.300</b>	<b>2012.8%</b>
<i>EBIT margin</i>	7.3%	4.7%	5.9%	0.3%	
Financial and other income (expenses), net	(0.444)	(0.075)	(0.519)	(0.488)	6.3%
Tax benefit (expenses)	(1.427)	(1.984)	(3.412)	(2.540)	34.3%
Share in Losses of Affiliate		(0.790)	(0.790)		
<b>Result for the period</b>	<b>1.940</b>	<b>(0.322)</b>	<b>1.618</b>	<b>(2.728)</b>	<b>n.m</b>
<b>EBITDA</b>	<b>7.234</b>	<b>7.140</b>	<b>14.374</b>	<b>5.949</b>	<b>141.6%</b>
<i>EBITDA margin</i>	13.8%	13.2%	13.5%	6.0%	

## EBIT Bridge

in USD millions

USD millions	First Half 2015	Second Half 2015	Total 2015	Total 2014
EBIT reported	3.811	2.527	6.338	0.300
LW V finished goods write-off	0.000	(1.200)	(1.200)	(5.050)
Adjusted EBIT	3.811	3.727	7.538	5.350
Adjusted EBIT margin	7.3%	6.9%	7.1%	5.4%
Adjusted EBITDA	7.234	8.340	15.574	10.999
Adjusted EBITDA margin	13.8%	15.4%	14.6%	11.2%

# Balance Sheet



USD millions	Dec. 31. 2015	Dec. 31. 2014	+/- in USD million
Balance sheet total	71.496	68.984	2.512
Cash and cash equivalents	7.400	7.087	0.313
Net working capital (NWC)	2.218	9.012	(6.794)
<i>NWC in % of revenues</i>	<i>2.08%</i>	<i>9.15%</i>	
Property, plant & equipment, net	16.348	14.922	1.43
Goodwill	15.859	14.976	0.88
Provisions	4.243	8.194	(3.950)
Interest-bearing debt	8.124	5.343	2.781
Net cash	(0.724)	1.744	(2.468)
<b>Equity</b>	<b>39.331</b>	<b>36.883</b>	<b>2.447</b>
Equity Ratio	55.0%	53.5%	

# Cash Flow



USD millions	Dec. 31. 2015	Dec. 31. 2014	+/- in USD million
Net cash from operating activities	9.146	4.089	5.057
Net cash from investing activities	(11.198)	(7.481)	(3.717)
Net cash from financial activities	2.365	0.496	1.869
Translation differences		(0.153)	0.153
<b>Increase (decrease) in cash and cash equivalents</b>	<b>0.313</b>	<b>(3.049)</b>	<b>3.362</b>
Balance of cash and cash equivalents at beginning of period	7.087	10.136	(3.049)
Balance of cash and cash equivalents at end of period	7.400	7.087	0.313



# Summary and Outlook



- Turnaround nearing completion, significant cost savings generated
- Fundamentally solid core business provides good platform for growth
- MCT 1-lead patch to be launched in the US in the first half of the year
- Sales in the Turkish market expected to start in the second half of the year
- INR business being launched in the US in Q2, 2016
- AliveCor co-operation expected to lead to first income in 2016
- Significant investment in renewing internal IT systems during 2016
- Above market growth rates expected to continue
- New market partnerships are being explored
- Adjusted EBIT, EBITDA and Net Income to continue to improve from the 2015 levels

Thank you for your interest!



Our experience  
and credentials let you  
take care of your life.

